• LAST PRICE
    1.9847
  • TODAY'S CHANGE (%)
    Trending Down-0.0353 (-1.7475%)
  • Bid / Lots
    1.9300/ 1
  • Ask / Lots
    2.1000/ 5
  • Open / Previous Close
    2.0200 / 2.0200
  • Day Range
    Low 1.9500
    High 2.0200
  • 52 Week Range
    Low 1.9500
    High 32.8500
  • Volume
    22,335
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.02
TimeVolumeTCRT
09:32 ET1922.02
09:33 ET1562.01
10:18 ET2272.004
10:29 ET1222.0123
10:45 ET1862.01
11:00 ET1502.010694
11:43 ET1002.01
11:54 ET1312.0017
12:06 ET7002.01
12:10 ET1002.01
12:17 ET1072.02
01:15 ET16732
01:18 ET51192.01
02:00 ET70121.96
02:02 ET20002.01
02:05 ET9192.01
02:20 ET1471.95
02:52 ET1001.9847
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTCRT
Alaunos Therapeutics Inc
3.2M
-0.2x
---
United StatesATXI
Avenue Therapeutics Inc
3.1M
-0.7x
---
United StatesENTO
Entero Therapeutics Inc
3.3M
0.0x
---
United StatesRASP
Actavia Life Sciences Inc
3.1M
-7.5x
---
United StatesREVB
Revelation Biosciences Inc
3.1M
0.0x
---
United StatesBPTH
Bio Path Holdings Inc
3.3M
0.0x
---
As of 2024-11-10

Company Information

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Contact Information

Headquarters
2617 Bissonnet St, Suite 225HOUSTON, TX, United States 77005
Phone
617-259-1970
Fax
617-241-2855

Executives

Independent Chairman of the Board
Holger Weis
Interim Chief Executive Officer, Director
Dale Hogue
Vice President - Finance
Ferdinand Groenewald
Independent Director
Robert Hofmeister
Independent Director
Robert Postma

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2M
Revenue (TTM)
$7.0K
Shares Outstanding
1.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.53
EPS
$-11.95
Book Value
$3.94
P/E Ratio
-0.2x
Price/Sales (TTM)
454.0
Price/Cash Flow (TTM)
---
Operating Margin
-278,857.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.